Tag: Checkpoint Inhibitor and ADC Combo

Home / Checkpoint Inhibitor and ADC Combo

Categories

Enfortumab vedotin-ejfv with pembrolizumab is approved by USFDA for locally advanced or metastatic urothelial carcinoma

Feb 2024: The Food and Drug Administration has sped up the approval process for two drugs, enfortumab vedotin-ejfv (Padcev, Astellas Pharma) and pembrolizumab (Keytruda, Merck). These drugs are meant...
checkpoint-inhibitor-and-adc-combo

Scan the code